Matthew J. Meyer is chief business advisor for life sciences at Wilson Sonsini Goodrich & Rosati. Based in San Francisco, Matthew leads the firm's life science business advisory practice—a newly formed, innovative resource aimed at providing start-up and emerging life sciences companies with business insights, capabilities, and strategies to help them thrive and address some of their most challenging issues.
Matthew is an experienced executive and attorney who has held diverse roles of increasing responsibility across a wide range of private and public biopharma, medtech, and precision medicine companies from start-ups to Fortune 50 in the U.S. and Europe, including Pfizer, Novartis, and CareDx. His leadership capabilities include delivery of strong commercial results, structuring and executing partnering transactions across the product life cycle, raising debt and equity capital in the private and public markets, and working with founders, management teams, and boards to address complex business issues to support rapid growth.
Prior to joining Wilson Sonsini, Matthew was managing director of Allwell Life Science Advisors, a boutique life science advisory firm focused on biotech start-ups and emerging growth companies. Previously, he was senior vice president of corporate development at Counsyl, a venture and private equity-backed personalized medicine company that was acquired by Myriad Genetics in 2018.
Matthew J. Meyer is chief business advisor for life sciences at Wilson Sonsini Goodrich & Rosati. Based in San Francisco, Matthew leads the firm's life science business advisory practice—a newly formed, innovative resource aimed at providing start-up and emerging life sciences companies with business insights, capabilities, and strategies to help them thrive and address some of their most challenging issues.
Matthew is an experienced executive and attorney who has held diverse roles of increasing responsibility across a wide range of private and public biopharma, medtech, and precision medicine companies from start-ups to Fortune 50 in the U.S. and Europe, including Pfizer, Novartis, and CareDx. His leadership capabilities include delivery of strong commercial results, structuring and executing partnering transactions across the product life cycle, raising debt and equity capital in the private and public markets, and working with founders, management teams, and boards to address complex business issues to support rapid growth.
Prior to joining Wilson Sonsini, Matthew was managing director of Allwell Life Science Advisors, a boutique life science advisory firm focused on biotech start-ups and emerging growth companies. Previously, he was senior vice president of corporate development at Counsyl, a venture and private equity-backed personalized medicine company that was acquired by Myriad Genetics in 2018.
- J.D., Villanova University School of Law
- B.A., Government, Cornell UniversityCum Laude
- State Bar of New York
- Not admitted in California
- J.D., Villanova University School of Law
- B.A., Government, Cornell UniversityCum Laude
- State Bar of New York
- Not admitted in California
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
- Privacy Policy
- Terms of Use
- Accessibility